成纤维细胞生长因子受体
医学
成纤维细胞生长因子受体1
癌症研究
酪氨酸激酶
生长因子受体
成纤维细胞生长因子受体2
成纤维细胞生长因子
受体酪氨酸激酶
成纤维细胞生长因子23
内科学
受体
钙
甲状旁腺激素
作者
M. Teresa Magone,Iris R. Hartley,Edmond J. FitzGibbon,Rachel Bishop,Mike Arango,Susan Moran,Roo Vold,Jaydira Del Rivero,Karen Pozo,Jamie Streit,Kelly L. Roszko,Michael T. Collins,Rachel I. Gafni
出处
期刊:Ophthalmology
[Elsevier BV]
日期:2020-09-01
卷期号:128 (4): 624-626
被引量:12
标识
DOI:10.1016/j.ophtha.2020.08.026
摘要
Fibroblast growth factor receptors (FGFRs) are expressed in all major organs, including the eye (Fig S1, available at www.aaojournal.org). 1 Chae Y.K. Ranganath K. Hammerman P.S. et al. Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application. Oncotarget. 2017; 8: 16052-16074 Crossref PubMed Scopus (183) Google Scholar Fibroblast growth factor receptor tyrosine kinase inhibitors (TKIs) are under investigation, targeting various cancer types. 1 Chae Y.K. Ranganath K. Hammerman P.S. et al. Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application. Oncotarget. 2017; 8: 16052-16074 Crossref PubMed Scopus (183) Google Scholar Furthermore, 2 FGFR-TKIs have recently been Food and Drug Administration-approved for treating advanced urothelial carcinoma and cholangiocarcinoma. Fibroblast growth factor receptor inhibition commonly leads to hyperphosphatemia, fatigue, stomatitis, alopecia, nail changes, dry eye, and blurred vision. 2 Javle M. Lowery M. Shroff R.T. et al. Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma. J Clin Oncol. 2018; 36: 276-282 Crossref PubMed Scopus (300) Google Scholar Re: Magone et al.: Ocular adverse effects of infigratinib, a new fibroblast growth factor receptor tyrosine kinase inhibitor (Ophthalmology. 2021;128:624–626)OphthalmologyVol. 128Issue 9PreviewWe read the article by Magone et al.1 The authors provide a useful description of the anterior segment findings in a small cohort of patients. However, we suspect there may be a discrepancy in their description of the posterior segment findings of one patient. They state that “None of the patients developed retinal pathology, including patient number 5, who had a history of reversible ingrafitinib-related bilateral retinal pigment epithelium detachments.” Although no longer present, we feel it important to comprehend this fundus abnormality fully. Full-Text PDF
科研通智能强力驱动
Strongly Powered by AbleSci AI